DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for osteogenesis imperfecta, type 21 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOsteogenesis imperfecta, type 21 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for osteogenesis imperfecta, type 21 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Osteogenesis imperfecta type XXI is not mentioned in any of the provided abstracts. The 2014 review covers types V through XII, all linked to mutations in non-collagenous genes such as BRIL, PEDF, CRTAP, P3H1, CYPB, HSP47, FKBP65, SP7, WNT1, TRIC-B, OASIS, and BMP1. Type XXI is absent from that list. The review states that most osteogenesis imperfecta cases are due to autosomal dominant type I collagen defects, while rare recessive forms arise from defects in genes whose protein products interact with collagen. No specific treatment for any type is discussed in that paper.
A 1981 review of systemic treatment for osteogenesis imperfecta reports that seventy percent of published articles at that time claimed beneficial results for twenty different agents, yet the authors conclude that no form of treatment has been accepted as effective. They state that no agent available at that time is of any value to the practitioner. The paper urges a high degree of skepticism toward positive results regardless of source. No drug is recommended.
A 2016 Spanish-language case study describes the educational inclusion of one university student with osteogenesis imperfecta in physical education classes. It documents the student’s stigmatisation, the teachers’ lack of knowledge about the disease, and the specific classroom adaptations made. No drug, treatment, or clinical outcome is reported.
No abstract provides any data on survival, response rates, or sample sizes for any treatment of osteogenesis imperfecta type XXI. What is missing is any clinical trial, any patient stratification by genetic subtype, and any funding directed specifically at type XXI.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Pediatrics · 2014 · 139 citations · open access
Osteogenesis imperfecta due to mutations in non-collagenous genes
AbstractPURPOSE OF REVIEW: Osteogenesis imperfecta or 'brittle bone disease' has mainly been considered a bone disorder caused by collagen mutations. Within the last decade, however, a surge of genetic discoveries has created a new paradigm for osteogenesis imperfecta as a collagen-related disorder, where most cases are due to autosomal dominant type I collagen defects, while rare, mostly recessive, forms are due to defects in genes whose protein products interact with collagen protein. This review is both timely and relevant in outlining the genesis, development, and future of this paradigm shift in the understanding of osteogenesis imperfecta. RECENT FINDINGS: Bone-restricted interferon-induced transmembrane (IFITM)-like protein (BRIL) and pigment epithelium-derived factor (PEDF) defects cause types V and VI osteogenesis imperfecta via defective bone mineralization, while defects in cartilage-associated protein (CRTAP), prolyl 3-hydroxylase 1 (P3H1), and cyclophilin B (CYPB) cause types VII-IX osteogenesis imperfecta via defective collagen post-translational modification. Heat shock protein 47 (HSP47) and FK506-binding protein-65 (FKBP65) defects cause types X and XI osteogenesis imperfecta via aberrant collagen crosslinking, folding, and chaperoning, while defects in SP7 transcription factor, wingless-type MMTV integration site family member 1 (WNT1), trimeric intracellular cation channel type b (TRIC-B), and old astrocyte specifically induced substance (OASIS) disrupt osteoblast development. Finally, absence of the type I collagen C-propeptidase bone morphogenetic protein 1 (BMP1) causes type XII osteogenesis imperfecta due to altered collagen maturation/processing. SUMMARY: Identification of these multiple causative defects has provided crucial information for accurate genetic counseling, inspired a recently proposed functional grouping of osteogenesis imperfecta types by shared mechanism to simplify current nosology, and has prodded investigations into common pathways in osteogenesis imperfecta. Such investigations could yield critical information on cellular and bone tissue mechanisms and translate to new mechanistic insight into clinical therapies for patients.
Clinical Orthopaedics and Related Research · 1981 · 40 citations
Systemic Treatment of Osteogenesis Imperfecta
AbstractSeventy percent of published articles on the medical treatment of osteogenesis imperfecta have claimed beneficial results for 20 different agents. This observation conflicts with current practice since no form of treatment has been accepted as effective in dealing with the disease. A few medications or combinations of medications hold some promise, but adequate documentation must be availble before they can be accurately assessed. It is essential that the practitioner maintain a high degree of skepticism toward positive results of treatment regardless of the source. At the present time, no agent is available which will be of any value to the practitioner who has a patient with osteogenesis imperfecta.
Estudios pedagógicos · 2016 · 10 citations · open access
Osteogénesis imperfecta y educación física: Un caso inédito de inclusión educativa
AbstractEl objetivo principal de este trabajo es indagar en la experiencia de inclusión educativa vivida por una alumna con osteogénesis imperfecta y por sus compañeras en una asignatura universitaria con contenidos relacionados con la educación física. La recogida de datos sobre la experiencia se realizó a lo largo de un cuatrimestre a partir de conversaciones informales con el profesor, entrevistas en profundidad y semi-estructuradas, y un cuestionario de respuesta abierta. El estudio revela la estigmatización sufrida por la alumna, tanto a nivel personal como académico (sobre todo en las clases de educación física) y el desconocimiento e inseguridad que manifiesta tener el futuro profesorado sobre esta enfermedad y cómo realizar un tratamiento inclusivo en sus clases. Asimismo, se describen las adaptaciones realizadas por el profesor de la asignatura con el fin de garantizar y ejemplificar la inclusión de una alumna con osteogénesis imperfecta en las clases de educación física.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
